CK
REGN icon

Carnick & Kubik’s Regeneron Pharmaceuticals REGN Stock Holding History

Carnick & Kubik’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		$89K Buy
+247
New +$102K 0.03% 571
2015
Q4 		– Sell
-247
Closed -$115K – 267
2015
Q3 		$115K Buy
+247
New +$133K 0.08% 164

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Carnick & Kubik's REGN Position: Q1 2016 in Review

Carnick & Kubik opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2016: 247 shares worth $89K. The stake represents 0.03% of the portfolio and ranks #571 among its holdings. This is a return to the name: Carnick & Kubik previously reported a position in REGN as recently as Q3 2015.

Carnick & Kubik first reported a position in REGN in Q3 2015 and has held it in 2 quarters since. The position peaked at $115K in Q3 2015. 549 funds tracked by Wall St. Rank hold REGN as of Q1 2016.

  • Carnick & Kubik held 247 shares of Regeneron Pharmaceuticals worth $89K as of Q1 2016.
  • Regeneron Pharmaceuticals was a new Carnick & Kubik position in Q1 2016.
  • Regeneron Pharmaceuticals made up 0.03% of Carnick & Kubik's portfolio in Q1 2016, its #571 holding.
  • Carnick & Kubik first reported a position in Regeneron Pharmaceuticals in Q3 2015 and has held it in 2 quarters since.
  • Carnick & Kubik's Regeneron Pharmaceuticals position peaked at $115K in Q3 2015.
  • 549 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2016.

Based on Carnick & Kubik's 13F filing for Q1 2016, filed 12 May 2016.